April F Eichler

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Multidisciplinary management of brain metastases
    April F Eichler
    Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Oncologist 12:884-98. 2007
  2. doi request reprint Survival in patients with brain metastases from breast cancer: the importance of HER-2 status
    April F Eichler
    Department of Neurology, Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer 112:2359-67. 2008
  3. ncbi request reprint Utility of administrative claims data for the study of brain metastases: a validation study
    April F Eichler
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 95:427-31. 2009
  4. pmc EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
    April F Eichler
    Pappas Center for Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Neuro Oncol 12:1193-9. 2010
  5. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
  6. pmc Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
  7. ncbi request reprint Randomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer
    Angelo E Volandes
    Massachusetts General Hospital, General Medicine Unit, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
    J Clin Oncol 31:380-6. 2013
  8. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
  9. pmc Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
    Christine Lu-Emerson
    Department of Neurology, Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Neuro Oncol 15:1079-87. 2013
  10. pmc Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
    David P Kodack
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 109:E3119-27. 2012

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Multidisciplinary management of brain metastases
    April F Eichler
    Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Oncologist 12:884-98. 2007
    ....
  2. doi request reprint Survival in patients with brain metastases from breast cancer: the importance of HER-2 status
    April F Eichler
    Department of Neurology, Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer 112:2359-67. 2008
    ..To the authors' knowledge, established prognostic factors for survival after the diagnosis of BM in breast cancer patients do not take into account HER-2 status, which may have increasing relevance in the trastuzumab therapy era...
  3. ncbi request reprint Utility of administrative claims data for the study of brain metastases: a validation study
    April F Eichler
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 95:427-31. 2009
    ..These results suggest that Medicare claims data may be used to evaluate clinical and epidemiological issues related to brain metastases in elderly cancer patients...
  4. pmc EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
    April F Eichler
    Pappas Center for Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Neuro Oncol 12:1193-9. 2010
    ..70-6.41) were independently associated with survival. In NSCLC patients with BM, EGFR mutation status is associated with improved survival, independent of age, functional status, extracranial disease status, and number of BMs...
  5. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
    ..nonresponders early in the course of this expensive and potentially toxic form of therapy, and these results may provide new insight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments. ..
  6. pmc Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
    ..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies...
  7. ncbi request reprint Randomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer
    Angelo E Volandes
    Massachusetts General Hospital, General Medicine Unit, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
    J Clin Oncol 31:380-6. 2013
    ..Decision making regarding cardiopulmonary resuscitation (CPR) is challenging. This study examined the effect of a video decision support tool on CPR preferences among patients with advanced cancer...
  8. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  9. pmc Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
    Christine Lu-Emerson
    Department of Neurology, Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Neuro Oncol 15:1079-87. 2013
    ..These data suggest that tumor-associated macrophages may participate in escape from antiangiogenic therapy and may represent a potential biomarker of resistance and a potential therapeutic target in recurrent glioblastoma. ..
  10. pmc Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
    David P Kodack
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 109:E3119-27. 2012
    ..These findings support the clinical development of this three-drug regimen for the treatment of HER2-amplified breast cancer brain metastases...
  11. pmc The biology of brain metastases-translation to new therapies
    April F Eichler
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Nat Rev Clin Oncol 8:344-56. 2011
    ..This Review discusses what is known about the biology of brain metastases, what preclinical models are available to study the disease, and which novel therapeutic strategies are being studied in patients...
  12. pmc Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss
    Matija Snuderl
    Pathology Service, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 2698, USA
    Clin Cancer Res 15:6430-7. 2009
    ..The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion...
  13. pmc Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate
    April F Eichler
    Pappas Center for Neuro Oncology, Boston, MA 02114, USA
    Neuro Oncol 9:373-7. 2007
    ..The absence of vascular or perfusion abnormalities suggests that transient cytotoxic edema in white matter may explain the syndrome of subacute MTX neurotoxicity...
  14. pmc Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial
    Areej El-Jawahri
    Departments of Medicine, Neurology and Cancer Center, and Oncology, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
    J Clin Oncol 28:305-10. 2010
    ..To determine whether the use of a goals-of-care video to supplement a verbal description can improve end-of-life decision making for patients with cancer...
  15. ncbi request reprint Brain metastases
    April F Eichler
    Scott R Plotkin, MD, PhD Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Curr Treat Options Neurol 10:308-14. 2008
    ....